Investing in Psychedelic Medicine FAQ

Explicit content warning

06/20/21 • 38 min

In this episode of The Integration Conversion, brom give a broad overview of the psychedelic investing landspace, and addresses come common misconceptions about investing in psychedelics.

Topics Include:

What does "investing in psychedelics" actually mean?
How big could the psychedelics market get?
What problems are psychedelics solving?
What are the different sub-segments of the psychedelic industry
Why is now the right time to get involved in the psychedelics industry?
Won't decriminalization destroy profits?
Aren't psychedelics just cannabis 2.0?

⏰ Timestamps:

0:00 - intro
5:00 - What exactly is "investing in psychedelics"?
8:00 - How is mental health currently treated?
10:00 - Mental health is trending in the wrong direction.
13:00 - How are psychedelics different?
13:45 - What types of businesses exist in the psychedelics industry?
20:00 - How to evaluate a psychedelic business?
22:30 - What business models should be avoided?
24:30 - Why is now the right time to invest in psychedelics?
27:30 - Is psychedelics just cannabis 2.0?
31:30 - Won't decriminalization destroy profits?

In this episode of The Integration Conversion, brom give a broad overview of the psychedelic investing landspace, and addresses come common misconceptions about investing in psychedelics.

Topics Include:

What does "investing in psychedelics" actually mean?
How big could the psychedelics market get?
What problems are psychedelics solving?
What are the different sub-segments of the psychedelic industry
Why is now the right time to get involved in the psychedelics industry?
Won't decriminalization destroy profits?
Aren't psychedelics just cannabis 2.0?

⏰ Timestamps:

0:00 - intro
5:00 - What exactly is "investing in psychedelics"?
8:00 - How is mental health currently treated?
10:00 - Mental health is trending in the wrong direction.
13:00 - How are psychedelics different?
13:45 - What types of businesses exist in the psychedelics industry?
20:00 - How to evaluate a psychedelic business?
22:30 - What business models should be avoided?
24:30 - Why is now the right time to invest in psychedelics?
27:30 - Is psychedelics just cannabis 2.0?
31:30 - Won't decriminalization destroy profits?

Previous Episode

Cybin CEO Doug Drysdale: Sublingual Psilocybin, Next-Gen Psychedelics & Brain Imaging Technology

Doug Drysdale is the CEO of Cybin, a psychedelic research company developing novel delivery systems for psilocybin, next-gen psychedelic tryptamine molecules and performing studies on human brains under the influence of psychedelics using powerful brain imaging technology. In this episode of the Integration Conversation, Brom and Doug cover all aspects of Cybin's business, and answer questions like:

Why is Cybin's sublingual psilocybin potentially superior to offerings from Compass Pathways and Usona?
How might deuterated tryptamines provide a superior psychedelic experience compared to classic psychedelics like psilocybin and LSD?
Why is Cybin's partnership with brain imaging company Kernel so powerful?
and the ultimate question for investors: is Cybin undervalued?

👇👇👇 Links 👇👇👇

📺 Watch on YouTube: https://youtu.be/cAsFHlVLpeA

💻 The Integration Co Website: https:/theintegration.co

📝 My notes on psychedelic investing: https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf

🎧 Listen on Spotify and other podcast platforms: https://anchor.fm/theintegrationco

🐦 brom on twitter: https://twitter.com/therealbrom

🎇 Clips and other stuff on Instagram: https://instagram.com/theintegrationco

💌 Email: [email protected]

⏰ Timestamps:

0:00 - intro / disclaimer / disclosures
4:20 - Cybin overview / Doug background
8:50 - What are the differences between traditional pharma & psychedelic pharma?
11:30 - How will Cybin deliver its drugs? Clinics?
13:00 - Cybin's sublingual psilocybin
15:45 - Is sublingual psilocybin as effective as normal psilocybin?
17:00 - More on Cybin and clinics
18:30 - is psychedelic decriminalization a threat to psychedelic pharma?
20:30 - Doug Drysdale on Compass Pathway's patents
22:00 - Cybin's Deuterated Tryptamines
24:30 - How does Cybin choose which drug will work for a given indication?
27:30 - What makes deuterated tryptamines different?
29:30 - Is reducing the hallucinogenic effect of psychedelics desirable?
32:00 - Cybin's inhalation and ODT delivery methods?
33:33 - Cybin's partnership with Kernel
40:00 - What are Cybin's upcoming catalysts?
42:00 - Is Cybin undervalued?
44:45 - Why is most psychedelic research being done by small startup companies?
47:00 - Is the psychedelic space overcrowded?
50:00 - Post-Interview analysis

Next Episode

Psychedelic Medicine Overview - What is Psychedelic Therapy + Three of My Favorite Psychedelic Research Studies

What exactly is psychedelic therapy, and what does the research on psychedelic therapy tell us about its effectiveness?

In this episode of The Integration Conversation, Brom provides a description of what exactly happens during psychedelic therapy, and then goes over the three most compelling clinical research papers on psychedelic therapy.

Learn about how MDMA can treat Post Traumatic Stress Disorder, psilocybin can treat depression, and how psilocybin stacks up against SSRIs like Lexapro.

👇 studies mentioned in this video

MDMA for PTSD https://www.nature.com/articles/s41591-021-01336-3

Trial of Psilocybin versus Escitalopram for Depression

https://www.nejm.org/doi/full/10.1056/NEJMoa2032994

Psilocybin to treat Depression and Anxiety in Cancer patients

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367557/

Psilocybin for smoking Cessation

https://files.csp.org/Psilocybin/Johnson2017Smoking.pdf

Ibogaine for Opioid Dependence

https://pubmed.ncbi.nlm.nih.gov/28402682/